Wrinkle appearance: a combined cosmetic patch
2Scope of investigation or explicitly identified community interest; not an established indication.
Acetyl octapeptide-3 in cosmetic formulations
Investigational; this profile does not establish an approved use.
Acetyl octapeptide-3 is a topical cosmetic ingredient promoted for expression lines; it is not equivalent to injected botulinum toxin.
Scope of investigation or explicitly identified community interest; not an established indication.
The peptide’s independent contribution was not isolated in the verified trial.2
2 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →No adverse effects were reported in 24 people over 28 days; that cannot rule out uncommon or long-term effects.2
Investigational; this profile does not establish an approved use.
8 residues · N → C14
Reference identity · not independently confirmed14
Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2Identity reported by Pep-Pedia; exact-product sequence and modifications have not been independently confirmed.
Acetyl octapeptide-3; distinct from acetyl hexapeptide-8/Argireline
Sequence and formulation must be confirmed for the exact material; similarly named products are not necessarily interchangeable.
8 amino acids · 1,075.16 Da
Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2Reference description; checked chemical identity above takes precedence when available.14
No numerical human elimination estimate is assigned from animal experiments, related molecules, or an unsupported website estimate.
No numerical estimate was found in the checked data or Pep-Pedia profile. A curve would require an unsupported assumption.
The peptide’s independent contribution was not isolated in the verified trial.2
Little change week 1; fine lines 2–3 weeks; visible effects 4–8; claimed fading 2–4 weeks after stopping.14
These are reported timelines, not a prediction of your response.
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
The source displays “216 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
Compare purpose, amount, route, frequency, and duration.
“Up to 63%” is not a typical expected result. Pairing/timing labels are not universal formulation rules.
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| TopicalTopical microneedle patch | Multi-ingredient patch; isolated peptide dose not stated in abstract | Overnight application; detailed frequency not stated in abstract | Periocular cosmetic outcomesHuman study | 28 days | 2 |
Population 24 healthy participants Context Results apply to the combined formulation. | |||||
| TopicalTopical serum/cream | 3-5% concentration | 2x daily | General Anti-AgingReference report | Continuous use - effects require ongoing application | 14 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. “Up to 63%” is not a typical expected result. Pairing/timing labels are not universal formulation rules. Source tabs Topical | |||||
| OtherTargeted application | 5-10% concentration | 2x daily | Intensive Wrinkle TreatmentReference report | Continuous use - effects require ongoing application | 14 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. “Up to 63%” is not a typical expected result. Pairing/timing labels are not universal formulation rules. Source tabs Topical | |||||
| OtherEye cream/serum | 3-5% concentration | 2x daily | Eye Area TreatmentReference report | Continuous use - effects require ongoing application | 14 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. “Up to 63%” is not a typical expected result. Pairing/timing labels are not universal formulation rules. Source tabs Topical | |||||
| OtherDirect application | 5-10% concentration | 2x daily | Forehead LinesReference report | Continuous use - effects require ongoing application | 14 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. “Up to 63%” is not a typical expected result. Pairing/timing labels are not universal formulation rules. Source tabs Topical | |||||
| OtherDaily moisturizer | 3% concentration | 1-2x daily | Preventive UseReference report | Continuous use - effects require ongoing application | 14 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. “Up to 63%” is not a typical expected result. Pairing/timing labels are not universal formulation rules. Source tabs Topical | |||||
| OtherMulti-peptide serum | 3-5% with other peptides | 2x daily | Combined Peptide ProtocolReference report | Continuous use - effects require ongoing application | 14 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. “Up to 63%” is not a typical expected result. Pairing/timing labels are not universal formulation rules. Source tabs Topical | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
After cleansing, before moisturizer
No adverse effects were reported in 24 people over 28 days; that cannot rule out uncommon or long-term effects.
2Cosmetic patch findings do not establish safety for injection or for an arbitrary serum concentration.
2Irritation, redness, burning, pigmentation changes or sensitivity.
Persistent irritation, allergy, worsening skin, eye irritation or vision changes.
Pregnancy/breastfeeding evidence insufficient; cosmetic mixture stability varies.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Check cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Irritation potential.14
Reference report · Pep-Pedia label: Use CautionReference pH/stability concern.14
Reference report · Pep-Pedia label: Requires TimingIrritation/stability concerns.14
Reference report · Pep-Pedia label: Use CautionSource cautions concurrent retinol.14
Reference report · Pep-Pedia label: Use CautionRelated mechanism; possibly redundant.14
Reference report · Pep-Pedia label: SynergisticExperimental inhibition findings.14
Reference report · Pep-Pedia label: SynergisticFormula-dependent pairing.14
Reference report · Pep-Pedia label: CompatibleHydration pairing.14
Reference report · Pep-Pedia label: SynergisticFormula-dependent pairing.14
Reference report · Pep-Pedia label: CompatibleUnproven combined benefit.14
Reference report · Pep-Pedia label: SynergisticA controlled interaction assessment for this exact compound and formulation was not identified in the sources checked. Absence of interaction data is not evidence of compatibility.3
Research contextNo matching interactions. Try another name or filter.
A product-specific preparation or sterility protocol has not been verified.3
A concentration calculation cannot establish a suitable diluent, compatibility, storage interval, or sterility. No universal bacteriostatic-water volume is assigned.3
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
The topical section discusses a finished serum or incorporation into a cosmetic base.
Do not equate a supplier blend percentage with pure peptide concentration.
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
The available sources describe prepared products or do not establish a reconstitution method.14
Solution at 4°C (refrigerated); powder at room temperature in cool, dark place
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
“Up to 63%” is not a typical expected result. Pairing/timing labels are not universal formulation rules.
SNAP-8 is acetyl octapeptide-3. A small human study tested it inside a multi-ingredient microneedle patch. Argireline, a different hexapeptide, is not automatically evidence for SNAP-8.
Other names: Acetyl octapeptide-3
Investigational; this profile does not establish an approved use.
Proposed interference with SNAP-25/SNARE-mediated neurotransmitter release; skin delivery limits interpretation.14
The active patch improved measured skin outcomes and had no reported adverse effects. It also contained a vitamin-C derivative and cyclic lysophosphatidic acid, so SNAP-8’s contribution is unresolved.
2Wrinkle appearance: a combined cosmetic patch. Scope of investigation or explicitly identified community interest; not an established indication.2
Pep-Pedia reports use in the research-peptide community. These reports are not clinical evidence.3
The percentage basis in Pep-Pedia’s 3–5% cosmetic table is not independently resolved; it may not represent pure active peptide. It is not a compounding formula.
Additional primary or regulatory sources were checked. No further 2025–2026 exact-compound clinical outcome study was identified in this targeted search; this is not evidence that none exists.
AI-prepared summaries. Independent medical editorial review is pending.
Original sources and review status. Open a reference to read its summary.
A 24-person 28-day trial compared a multi-ingredient microneedle patch with a hyaluronic-acid patch.
Pep-Pedia bibliography · Checked 2026-10-12
A 24-person 28-day trial compared a multi-ingredient microneedle patch with a hyaluronic-acid patch.
The active patch improved measured skin outcomes and had no reported adverse effects. It also contained a vitamin-C derivative and cyclic lysophosphatidic acid, so SNAP-8’s contribution is unresolved.
Additional research · Checked 2026-10-12
Secondary community overview checked on 12 October 2026. Its practice tables and efficacy claims are not independently validated clinical guidance.
Pep-Pedia reports: The review surveys skin-aging peptide mechanisms, including neurotransmitter modulation; it is not a direct controlled SNAP-8 efficacy trial.
Reported population / model
Review
Reported study details
Comprehensive peptide analysis · Anti-aging mechanisms
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: The trial concerned Argireline, a related hexapeptide, with improved wrinkle measures; it cannot directly validate SNAP-8.
Reported population / model
Human
Reported study details
10% solution · 4 weeks · 60 Chinese subjects
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Argireline is a different hexapeptide, not SNAP-8 acetyl octapeptide-3.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: The source reports SNARE-related inhibition in laboratory assays, including combinations; topical clinical outcomes require separate evidence.
Reported population / model
In vitro
Reported study details
1.5 mM concentration · Catecholamine release assay
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: The study developed an analytical assay for SNAP-8 in formulations and microneedle systems; quantification is not proof of anti-wrinkle efficacy.
Reported population / model
Analytical
Reported study details
Mass spectrometry · Microneedle patch quantification
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: The reported up-to-30% wrinkle-depth reduction concerns Argireline, not the longer SNAP-8 sequence.
Reported population / model
Human
Reported study details
10% O/W emulsion · 30 days · Skin topography analysis
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Argireline is a different hexapeptide, not SNAP-8 acetyl octapeptide-3.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12